Zoetis Inc. (NYSE:ZTS) Position Cut by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC trimmed its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 2.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 161,999 shares of the company's stock after selling 3,691 shares during the period. Nisa Investment Advisors LLC's holdings in Zoetis were worth $26,673,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after purchasing an additional 120,158 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Zoetis by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock worth $1,726,075,000 after acquiring an additional 190,137 shares during the period. Polen Capital Management LLC lifted its holdings in shares of Zoetis by 17.5% during the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock worth $1,219,237,000 after acquiring an additional 1,116,541 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock worth $1,133,755,000 after acquiring an additional 3,059,255 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Zoetis by 13.3% during the 4th quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock worth $1,047,052,000 after acquiring an additional 755,893 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Zoetis stock traded up $0.54 during mid-day trading on Thursday, reaching $158.81. The company's stock had a trading volume of 3,491,008 shares, compared to its average volume of 2,590,248. The firm has a market cap of $70.70 billion, a price-to-earnings ratio of 28.51, a PEG ratio of 2.62 and a beta of 0.91. The business has a 50 day moving average price of $161.30 and a 200-day moving average price of $161.97. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm's revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.38 earnings per share. Sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.26%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio is presently 35.91%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ZTS shares. UBS Group cut their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Piper Sandler increased their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Finally, Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of "Buy" and an average price target of $212.13.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.18% of the stock is currently owned by corporate insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.